CBER Lot Release Requirement Should Be Eliminated – PhRMA
Executive Summary
The lot release requirement for biologics should be eliminated, the Pharmaceutical Research & Manufacturers of America maintained in comments submitted to the HHS Advisory Committee on Regulatory Reform
You may also be interested in...
Greenwood/DeGette Human Subject Protection Bill Has Support Of ACRO
HHS would be directed to harmonize FDA's clinical trial oversight regulations with the common rule under the Greenwood/DeGette human subject protection bill
Greenwood/DeGette Human Subject Protection Bill Has Support Of ACRO
HHS would be directed to harmonize FDA's clinical trial oversight regulations with the common rule under the Greenwood/DeGette human subject protection bill
Clinical Trial Oversight Training Programs For IRBs Recommended By BIO
Institutional Review Boards need better training for clinical trial oversight, not new rules governing procedures, the Biotechnology Industry Organization suggests